Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study.
Snowden SG, Ebshiana AA, Hye A, An Y, Pletnikova O, O'Brien R, Troncoso J, Legido-Quigley C, Thambisetty M. · 2017
Read Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study. by Snowden SG, Ebshiana AA, Hye A, An Y, Pletnikova O, O'Brien R, Troncoso J, Legido-Quigley C, Thambisetty M. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5360226.txt.
Introduction
Stuart G. Snowden and co-authors probed fat chemistry in Alzheimer's brains in PLoS Medicine in 2017. The metabolic roots of the disease are poorly mapped. Two fat families, omega-3 and omega-6, had been tied to both guarding and harming effects in past work. How their levels shift with the amount of disease in the brain was unknown.
The team profiled thousands of small chemicals in brain tissue from more than forty donors in a long Baltimore aging study. The donors split into three groups: full disease, healthy, and a middle group with heavy brain signs but no memory loss in life. Six unsaturated fats split the groups cleanly. Some ran far lower in disease brains, one ran higher. The pattern held in zones the disease hits hard. Fat handling, they argue, is badly off tune across the disease span.
Catalog record
| CREATOR | Snowden SG, Ebshiana AA, Hye A, An Y, Pletnikova O, O'Brien R, Troncoso J, Legido-Quigley C, Thambisetty M. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | CC0 1.0 Universal |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study By Stuart G. Snowden, Amera A. Ebshiana, Abdul Hye, Yang An, Olga Pletnikova, Richard O’Brien, John Troncoso, Cristina Legido-Quigley, Madhav Thambisetty, Carol Brayne Published in: PLoS Medicine DOI: 10.1371/journal.pmed.1002266 ABSTRACT Background The metabolic basis of Alzheimer disease (AD) pathology and expression of AD symptoms is poorly understood. Omega-3 and -6 fatty acids have previously been linked to both protective and pathogenic effects in AD. However, to date little is known about how the abundance of these species is affected by differing levels of disease pathology in the brain. Methods and findings We performed metabolic profiling on brain tissue samples from 43 individuals ranging in age from 57 to 95 y old who were stratified into three groups: AD (N = 14), controls (N = 14) and “asymptomatic Alzheimer’s disease” (ASYMAD), i.e., individuals with significant AD neuropathology at death but without evidence for cognitive impairment during life (N = 15) from the autopsy sample of the Baltimore Longitudinal Study of Aging (BLSA). We measured 4,897 metabolite features in regions both vulnerable in the middle frontal and inferior temporal gyri (MFG and ITG) and resistant (cerebellum) to classical AD pathology. The levels of six unsaturated fatty acids (UFAs) in whole brain were compared in controls versus AD, and the differences were as follows: linoleic acid (p = 8.8 x 10−8, FC = 0.52, q = 1.03 x 10−6), linolenic acid (p = 2.5 x 10−4, FC = 0.84, q = 4.03 x 10−4), docosahexaenoic acid (p = 1.7 x 10−7, FC = 1.45, q = 1.24 x 10−6), eicosapentaenoic acid (p = 4.4 x 10−4, FC = 0.16, q = 6.48 x 10−4), oleic acid (p = 3.3 x 10−7, FC = 0.34, q = 1.46 x 10−6), and arachidonic acid (p = 2.98 x 10−5, FC = 0.75, q = 7.95 x 10−5). These fatty acids were strongly associated with AD when comparing the groups in the MFG and ITG, respectively: linoleic acid (p < 0.0001, p = 0.0006), linolenic acid (p < 0.0001, p = 0.002), docosahexaenoic acid (p < 0.0001, p = 0.0024), eicosapentaenoic acid (p = 0.0002, p = 0.0008), oleic acid (p < 0.0001, p = 0.0003), and arachidonic acid (p = 0.0001, p = 0.001). Significant associations were also observed between the abundance of these UFAs with neuritic plaque and neurofibrillary tangle burden as well as domain-specific cognitive performance assessed during life. Based on the regional pattern of differences in brain tissue levels of these metabolites, we propose that alterations in UFA metabolism represent both global metabolic perturbations in AD as well as those related to specific features of AD pathology. Within the middle frontal gyrus, decrements in linoleic acid, linolenic acid, and arachidonic acid (control>ASYMAD>AD) and increases in docosahexanoic acid (AD>ASYMAD>control) may represent regionally specific threshold levels of these metabolites beyond which the accumulation of AD pathology triggers the expression of clinical symptoms. The main limitation of this study is the relatively small sample size. There are few cohorts with extensive longitudinal cognitive assessments during life and detailed neuropathological assessments at death, such as the BLSA Conclusions The findings of this study suggest that unsaturated fatty acid metabolism is significantly dysregulated in the brains of patients with varying degrees of Alzheimer pathology. INTRODUCTION Alzheimer disease (AD) is a neurodegenerative disorder characterised by progressive cognitive decline, with impairment in multiple cognitive domains including memory, executive function, and language [1]. AD accounts for between 60% and 80% of total dementia cases worldwide [2] and represents a major cause of global morbidity and mortality. It is currently estimated that there are over 46 million people suffering from the disease worldwide, with the number of patients estimated to rise to 131.5 million by 2050 [3]. As well as a major human cost, dementia also imposes a significant economic impact costing US$818 billion in 2015, and estimated to rise to US$1 trillion by 2018 [3]. Extracellular accumulation of amyloid-β (Aβ) plaques and intracellular accumulation of neurofibrillary tangles are the pathological hallmarks of AD. A growing body of evidence suggests that metabolic perturbations in various pathways may mediate the occurrence of Alzheimer pathology as well as the onset of cognitive impairment in patients [4]. The application of large-scale unbiased metabolomics techniques to study the role of metabolism in Alzheimer pathogenesis may facilitate a more complete understanding of Alzheimer pathology and mechanisms triggering symptom expression. Metabolomics can be defined as “the unbiased analysis of the composition of small molecule metabolites in a given biological tissue or fluid under a specific set of environmental conditions” [5–7]. Several metabolomic studies have previously examined the relationship between metabolism and AD pathology. While studies on serum, plasma, and cerebrospinal fluid have identified several metabolic pathways involving bile acids, sphingolipids, antioxidants, phospholipids, and amino acids that appear to be associated with disease [8–13], it is likely that metabolomic studies on human brain tissue samples may provide direct insights into the molecular basis of Alzheimer pathogenesis. A handful of studies have performed metabolomics on brain tissue samples from both transgenic animal models and humans. Salek et al. found alterations in neurotransmitters, amino acids and antioxidants to be strongly associated with AD [14]. Graham et al. [15] used metabolomics to analyze human brain neocortex samples (15 controls versus 15 AD) and were able to differentiate controls and AD samples, [15]. Inoue et al. analyzed the parietal and frontal lobes of healthy controls and Alzheimer patients (10 versus 10) and identified increased brain polyamine metabolism in AD brains [16]. In AD, there is a regional specificity in the vulnerability of various brain regions to pathology, with some regions exhibiting greater amyloid pathology whilst others are dominated by neurofibrillary tangles [17,18]. However, previous studies have not examined changes in brain metabolite profiles in relation to the regional distribution of disease pathology. Equally important, few studies have addressed the relationships between brain metabolite signatures and the manifestation of clinical symptoms of AD in response to pathology. It is now well recognized that substantial levels of Alzheimer pathology can occur in the brains of cognitively normal individuals [19]. In the Baltimore Longitudinal Study of Aging (BLSA), we have categorized this group of individuals as “asymptomatic Alzheimer’s disease” (ASYMAD) [20], i.e., subjects with significant AD neuropathology at death but without evidence for cognitive impairment during life, as assessed by longitudinal cognitive assessments [20]. In this study, we applied untargeted metabolomics to brain tissue collected through the autopsy sample of the BLSA in three groups of individuals (AD; N = 14, control; N = 14 and ASYMAD; N = 15) and studied differences in brain metabolite levels within regions both vulnerable and resistant to AD pathology. We thus examined the middle frontal gyrus (MFG; vulnerable to Aβ deposition), inferior temporal gyrus (ITG; vulnerable to tau deposition), and the cerebellum (CB), which is relatively spared of classical AD pathology [21]. The relationships between metabolic shifts and specific features of Alzheimer pathology and disease outcome were assessed by applying untargeted metabolomics utilizing liquid chromatography–mass spectrometry (LC-MS) and gas chromatography–mass spectrometry (GC-MS) to maximize the metabolite coverage obtained. MATERIALS AND METHODS Sample information The ethics approval was obtained from